Neutropenic enterocolitis: Difference between revisions
No edit summary |
m (Rossdonaldson1 moved page Neutropenic enterocolitis (typhlitis) to Neutropenic enterocolitis) |
||
| (5 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
[[File:Diameters of the large intestine.png|thumb|Average inner diameters and ranges of different sections of the large intestine.<ref> Nguyen H, Loustaunau C, Facista A, Ramsey L, Hassounah N, Taylor H, et al. (July 2010). "Deficient Pms2, ERCC1, Ku86, CcOI in field defects during progression to colon cancer". Journal of Visualized Experiments (41). doi:10.3791/1931. PMC 3149991. PMID 20689513.</ref>]] | |||
*Also known as "typhlitis" | |||
*Necrosis of bowel wall secondary to polymicrobial invasion | *Necrosis of bowel wall secondary to polymicrobial invasion | ||
**Involves terminal ileum and colon | **Involves terminal ileum and colon | ||
**May progress to full-thickness infarction/perforation | **May progress to full-thickness infarction/perforation | ||
==Clinical Features== | ==Clinical Features== | ||
*Fever | *Typically presents 10-14d after cytotoxic therapy | ||
*RLQ pain | *[[neutropenic fever|Fever]] | ||
*Nausea | *[[RLQ pain]] | ||
*[[Nausea/vomiting]] | |||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
| Line 17: | Line 18: | ||
==Evaluation== | ==Evaluation== | ||
===Workup<ref>Machado NO. Neutropenic enterocolitis: A continuing medical and surgical challenge. N Am J Med Sci. 2010 Jul; 2(7): 293–300.</ref>=== | ===Workup<ref>Machado NO. Neutropenic enterocolitis: A continuing medical and surgical challenge. N Am J Med Sci. 2010 Jul; 2(7): 293–300.</ref>=== | ||
*CBC with neutropenia, thrombocytopenia | *CBC with [[neutropenia]], [[thrombocytopenia]] | ||
*Blood cultures positive in ~25-85%, frequently bowel organisms | *Blood cultures positive in ~25-85%, frequently bowel organisms | ||
*CT A/P: cecal distention, wall thickening, pneumatosis intestinalis, intestinal perforation, fat stranding | *CT A/P: cecal distention, wall thickening, pneumatosis intestinalis, intestinal perforation, fat stranding | ||
| Line 23: | Line 24: | ||
==Management== | ==Management== | ||
*Bowel rest | |||
*[[NG tube]] to suction | |||
*[[IVF]] | |||
*TPN | |||
*Consider G-CSF, particularly neutropenia < 100/ml and severe disease<ref>Greil R, Psenak O, Roila F. ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol. 2008;19(suppl 2:ii):116–1118.</ref> | |||
*Broad spectrum antimicrobials, in particular against gut microbiota to include<ref>Gorschluter M, Mey U, Strehl J, Zinske C, Schepke M, Schmid F, Wolf IG, Sauerbruch T, Glasmacher A, et al. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol. 2005;75(1):1–13.</ref>: | |||
**[[Metronidazole]] plus [[cefepime]] | |||
**[[Piperacillin-tazobactam]] | |||
**[[Amphotericin B]] when patient remains febrile, neutropenic for greater than 5 days despite broad spectrum antibiotics | |||
*Surgical consult (possible need for right hemicolectomy)<ref>Williams N, Scott AD. Neutropaenic enterocolitis : a continuing surgical challenge. Br J Surg. 1997;84(9):1200–1205.</ref> | |||
==Disposition== | ==Disposition== | ||
* | *Admit | ||
==See Also== | ==See Also== | ||
*[[Neutropenic fever]] | *[[Neutropenic fever]] | ||
== | |||
==References== | |||
<references/> | <references/> | ||
[[Category:GI]] | [[Category:GI]] | ||
[[Category:ID]] | [[Category:ID]] | ||
[[category:Surgery]] | |||
[[Category:Heme/Onc]] | |||
Latest revision as of 21:10, 24 September 2025
Background
Average inner diameters and ranges of different sections of the large intestine.[1]
- Also known as "typhlitis"
- Necrosis of bowel wall secondary to polymicrobial invasion
- Involves terminal ileum and colon
- May progress to full-thickness infarction/perforation
Clinical Features
- Typically presents 10-14d after cytotoxic therapy
- Fever
- RLQ pain
- Nausea/vomiting
Differential Diagnosis
Oncologic Emergencies
Related to Local Tumor Effects
- Malignant airway obstruction
- Bone metastases and pathologic fractures
- Malignant spinal cord compression
- Malignant Pericardial Effusion and Tamponade
- Superior vena cava syndrome
Related to Biochemical Derangement
- Hypercalcemia of malignancy
- Hyponatremia due to SIADH
- Adrenal insufficiency
- Tumor lysis syndrome
- Carcinoid syndrome
Related to Hematologic Derangement
Related to Therapy
- Chemotherapy-induced nausea and vomiting
- Cytokine release syndrome
- Chemotherapeutic drug extravasation
- Differentiation syndrome (retinoic acid syndrome) in APML
- Stem cell transplant complications
- Catheter-related complications
- Tunnel infection
- Exit site infection
- CVC obstruction (intraluminal or catheter tip thrombosis)
- Catheter-related venous thrombosis
- Fracture of catheter lumen
- Oncologic therapy related adverse events
RLQ Pain
- GI
- Appendicitis
- Perforated appendicitis
- Peritonitis
- Crohn's disease (terminal ileitis)
- Diverticulitis (cecal, Asian patients)
- Inguinal hernia
- Mesenteric ischemia
- Ischemic colitis
- Meckel's diverticulum
- Neutropenic enterocolitis (typhlitis)
- Appendicitis
- GU
- Other
Evaluation
Workup[2]
- CBC with neutropenia, thrombocytopenia
- Blood cultures positive in ~25-85%, frequently bowel organisms
- CT A/P: cecal distention, wall thickening, pneumatosis intestinalis, intestinal perforation, fat stranding
- Avoid endoscopic evaluation due to risk of perforation, hemorrhage, bacterial translocation, worsening sepsis
Management
- Bowel rest
- NG tube to suction
- IVF
- TPN
- Consider G-CSF, particularly neutropenia < 100/ml and severe disease[3]
- Broad spectrum antimicrobials, in particular against gut microbiota to include[4]:
- Metronidazole plus cefepime
- Piperacillin-tazobactam
- Amphotericin B when patient remains febrile, neutropenic for greater than 5 days despite broad spectrum antibiotics
- Surgical consult (possible need for right hemicolectomy)[5]
Disposition
- Admit
See Also
References
- ↑ Nguyen H, Loustaunau C, Facista A, Ramsey L, Hassounah N, Taylor H, et al. (July 2010). "Deficient Pms2, ERCC1, Ku86, CcOI in field defects during progression to colon cancer". Journal of Visualized Experiments (41). doi:10.3791/1931. PMC 3149991. PMID 20689513.
- ↑ Machado NO. Neutropenic enterocolitis: A continuing medical and surgical challenge. N Am J Med Sci. 2010 Jul; 2(7): 293–300.
- ↑ Greil R, Psenak O, Roila F. ESMO Guidelines Working Group. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol. 2008;19(suppl 2:ii):116–1118.
- ↑ Gorschluter M, Mey U, Strehl J, Zinske C, Schepke M, Schmid F, Wolf IG, Sauerbruch T, Glasmacher A, et al. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol. 2005;75(1):1–13.
- ↑ Williams N, Scott AD. Neutropaenic enterocolitis : a continuing surgical challenge. Br J Surg. 1997;84(9):1200–1205.